Bioresponsive Cytokine Delivery Responding to Matrix Metalloproteinases.
Björn Ter MorsValerie SpielerEduardo Merino AsumendiBenedikt GantertTessa LühmannLorenz MeinelPublished in: ACS biomaterials science & engineering (2023)
Cytokines are regulated in acute and chronic inflammation, including rheumatoid arthritis (RA) and myocardial infarction (MI). However, the dynamic windows within which cytokine activity/inhibition is desirable in RA and MI change timely and locally during the disease. Therefore, traditional, static delivery regimens are unlikely to meet the idiosyncrasy of these highly dynamic pathophysiological and individual processes. Responsive delivery systems and biomaterials, sensing surrogate markers of inflammation (i.e., matrix metalloproteinases - MMPs) and answering with drug release, may present drug activity at the right time, manner, and place. This article discusses MMPs as surrogate markers for disease activity in RA and MI to clock drug discharge to MMP concentration profiles from MMP-responsive drug delivery systems and biomaterials.
Keyphrases
- disease activity
- rheumatoid arthritis
- drug release
- systemic lupus erythematosus
- ankylosing spondylitis
- rheumatoid arthritis patients
- oxidative stress
- drug induced
- cancer therapy
- juvenile idiopathic arthritis
- drug delivery
- interstitial lung disease
- tissue engineering
- liver failure
- cell migration
- respiratory failure
- heart failure
- transcription factor
- left ventricular
- hepatitis b virus
- adverse drug
- extracorporeal membrane oxygenation
- systemic sclerosis